U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07447050) titled 'Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial' on Feb. 25.
Brief Summary: This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.
Study Start Date: Dec. 23, 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Sarcoma
Gastric (Stomach) Cancer
Lung Cancer
Head and Neck Cancer
Colorectal Cancer
Ovarian Cancer
Liver Cancer
Genitourinary Cancer
Gynecologic Cancer
Intervention:
DRUG: Riluzole
Given PO
...